The density, location, and function of immune cells in the tumor microenvironment (TME), especially CD8+ T cells, are prognostic in melanoma [1–6] and other cancers [7–9], and can predict patient responses to immunomodulating therapies [10–13]. The gene discussed is CD8A; the disease is melanoma.